Dear Colleagues,

Welcome to the 2019 Update in General Cardiology during the C³ Conference in Orlando, Florida.

We are fortunate to witness rapid advances in cardiovascular science that add new options to us for the clinical management of our patients. While this progress is exciting, it also presents a challenge to practitioners. How do we keep up with the plethora of new information? How do we sort the wheat from the chaff? How do we judge what new studies and therapeutic options are applicable to our patients as we encounter them in our daily practice? How do we make the difficult choices about integrating novel therapies with the tried and true?

The burgeoning general cardiovascular program within the C³ Symposium aims to provide guidance to the practitioner regard these points. Expert speakers, all of whom practice clinical cardiology as well as engage in forefront research, distill the essence of the rapidly expanding knowledge base and provide a seasoned perspective on how to integrate this information into practice. Discussion among the experts airs the controversies and strengths and weaknesses regarding late-breaking clinical trials.

Where do we stand with aspirin in primary prevention in 2019? Are omega-3 fatty acids right for some of our patients? Who benefits from low dose oral anticoagulants? What is the latest information about how we can forestall re-admissions for heart failure? Whom should we refer for mitral valve intervention, what kind, and when?

Together we weigh the pros and cons of emerging therapeutic options. Using a case-based approach we put the research information into a practical context. The assembled experts interact with the attendees to elicit their insightful questions and to share best practices. We have worked hard to put together a program that will prove informative as well as exciting and invite you to join us in Orlando in June.

Thank you for your participation in this year’s Update in General Cardiology at C³. Enjoy the program!

Peter Libby, MD  
Brigham and Women’s Hospital/Harvard Medical School  
Boston, MA  
Chair, General Cardiology Program

Rajesh Dave, MD, FSCAI, FACC  
The Ortenzio Heart Center at Holy Spirit Hospital  
Camp Hill, PA  
Chairman, C³ Global Conference
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School. Dr. Bhatt has been listed in Best Doctors in America from 2005 to 2018. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar. He has over 1,100 publications and is listed as a Thomson Reuters Highly Cited Researcher. He is Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease.

Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology. He received his medical doctorate from Cornell University. He completed a Master in Public Health with a concentration in clinical effectiveness at Harvard University. His residency in internal medicine was performed at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic.
<table>
<thead>
<tr>
<th>Full Name</th>
<th>College/University</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuel Asirvatham, MD</td>
<td>Mayo Clinic</td>
<td>Rochester, MN</td>
</tr>
<tr>
<td>Karim Al-Azizi, MD</td>
<td>Baylor Scott &amp; White The Heart Hospital - Plano</td>
<td>Plano, TX</td>
</tr>
<tr>
<td>Steven Bailey, MD, MSCAI</td>
<td>UT Health San Antonio</td>
<td>San Antonio, TX</td>
</tr>
<tr>
<td>Sripal Bangalore, MD, MHA</td>
<td>NYU Langone Health</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC</td>
<td>Brigham and Women’s Hospital/ Harvard Medical School</td>
<td>Newton, MA</td>
</tr>
<tr>
<td>Wendy Bottinor, MD</td>
<td>University of Louisville Hospital</td>
<td>Louisville, KY</td>
</tr>
<tr>
<td>Marc Bonaca, MD, MPH</td>
<td>University of Colorado School of Medicine</td>
<td>Aurora, CO</td>
</tr>
<tr>
<td>Alan Brown, MD</td>
<td>Advocate Good Samaritan Hospital &amp; Advocate Lutheran General Hospital</td>
<td>Naperville, IL</td>
</tr>
<tr>
<td>John Cahill, MD, FACC</td>
<td>East Carolina Heart Institute at ECU</td>
<td>Greenville, NC</td>
</tr>
<tr>
<td>Blasé Carabello, MD</td>
<td>East Carolina Heart Institute at ECU</td>
<td>Greenville, NC</td>
</tr>
<tr>
<td>Teresa Carman, MD</td>
<td>University Hospitals Cleveland Medical Center</td>
<td>Cleveland, OH</td>
</tr>
<tr>
<td>V. Chockalingam, MD, DNB</td>
<td>MGR Medical University</td>
<td>Chennai, India</td>
</tr>
<tr>
<td>Ramesh Daggubati, MD, FACC, FSCAI</td>
<td>NYU Winthrop Hospital</td>
<td>Mineola, NY</td>
</tr>
<tr>
<td>Steven Dean, DO, FSVM, RPVI</td>
<td>The Ohio State University</td>
<td>Columbus, OH</td>
</tr>
<tr>
<td>Prakash Deedwania, FACC, FAHA, FESC</td>
<td>UCSF School of Medicine/UCSF Fresno</td>
<td>Fresno, CA</td>
</tr>
<tr>
<td>Nihar Desai, MD, MPH</td>
<td>Yale School of Medicine</td>
<td>Shelton, CT</td>
</tr>
<tr>
<td>T.S. Dharmarajan, MD, MACP, FRCPE</td>
<td>Montefiore Medical Center</td>
<td>Scarsdale, NY</td>
</tr>
<tr>
<td>Parag Doshi, MD, FSCAI</td>
<td>Chicago Cardiology Institute</td>
<td>Schaumburg, IL</td>
</tr>
<tr>
<td>Christian Erbel, MD</td>
<td>University Hospital Heidelberg</td>
<td>Heidelberg, Germany</td>
</tr>
<tr>
<td>Michael Ezekowitz, MBChB, DPhil</td>
<td>The Lankenau Institute for Medical Research</td>
<td>Villanova, PA</td>
</tr>
<tr>
<td>James Fang, MD</td>
<td>University of Utah</td>
<td>Salt Lake City, UT</td>
</tr>
<tr>
<td>Sergio Fazio, MD, PhD</td>
<td>Oregon Health &amp; Science University</td>
<td>Portland, OR</td>
</tr>
</tbody>
</table>
Faculty Listing

Jennifer Robinson, MD
The University of Iowa
Iowa City, IA

Vivian Rocha, MD
Ibmec Business School
Rio de Janeiro, Brazil

Christian Ruff, MD, MPH
Brigham and Women’s Hospital
& TIMI Study Group
Boston, MA

Rajesh Sachdeva, MD
Morehouse School of Medicine
Atlanta, GA

Robert Safian, MD, FSCAI
Beaumont Health
Royal Oak, MI

Aditya Sharma, MBBS
University of Virginia
Charlottesville, VA

Parikshit Sharma, MD, MPH
Rush University Medical Center
Chicago, IL

Holger Thiele, MD
Leipzig University Hospital
Leipzig, Germany

Mintu Turakhia, MD, MAS
Stanford Health Care
Stanford, CA

Tudor Vagaonescu, MD, FSCAI
Rutgers RWJ University Hospital
New Brunswick, NJ

Anthony Venbrux, MD
The George Washington
University Medical Center
Washington, District of Columbia

George Vetrovec, MD,
MACC, MScAI
Virginia Commonwealth
University
Richmond, VA

Mary Norine Walsh, MD, FACC
St. Vincent Medical Group - Indianapolis
Indianapolis, IN

Paul Whelton, MD, MSc
Tulane University
New Orleans, LA

David Wood, MD, FRCPC
University of British Columbia
Vancouver, Canada

Roman Zeltser, MD, FACC
Nassau University Medical Center
& Zucker School of Medicine at Hofstra/Northwell
Syosset, NY
CME Information

ACCREDITATION STATEMENT
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
This activity is approved for AMA PRA Category 1 Credits™.

FUNDING
C³ 2019 is funded by educational grants from various commercial organizations, which have no control over program content. Please visit www.c3conference.net for a list of commercial supporters and contributors from the 2018 conference. A final list will be available onsite.

DISCLOSURE INFORMATION
Current guidelines require that participants in CME/CE activities be made aware of all affiliations or financial interests that may be perceived as affecting the presentation of the faculty member. ACHL ensures that all faculty and staff involved in the planning, development, and implementation of ACHL activities disclose all potential conflicts of interest and resolve them before the CME/CE activity occurs. Complete information will be provided to participants prior to the start of the educational activity.
Schedule

Sunday, June 23, 2019

NOAC in Stroke Prevention for NVAF
Chair: Christian Ruff, MD, MPH
Co-Chairs: Michael Ezekowitz, MBChB, DPhil, Renato Lopes, MD, PhD,
Sean Pokorney, MD, MBA

• Welcome and Introduction..................................................Christian Ruff, MD, MPH
• AF Guideline Update: What Does Every Clinician Need to Know? ..................Christian Ruff, MD, MPH
• Screening for AF: Should We Be Doing It and How?.....................Michael Ezekowitz, MBChB, DPhil
• Subclinical AF: How Much AF is Enough to Warrant Anticoagulation?...............Sean Pokorney, MD, MBA
• Is There a Role for Biomarkers in Risk Stratification for AF? ..................Christian Ruff, MD, MPH
• Can We Use NOACs in ESRD?...........Michael Ezekowitz, MBChB, DPhil
• What is the Optimal Combination Therapy in Patients with AF + CAD? ..................Renato Lopes, MD, PhD

League of Luminaries and Keynote Lecture
Chairs:  Ramesh Daggubati, MD, FACC, FSCAI, Alan Brown, MD,
Rajesh Dave, MD, Nihar Desai, MD, MPH, Peter Libby, MD,
Christian Ruff, MD, MPH

• Introduction of Keynote Speaker and Award Distribution – Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC ......Ramesh Daggubati, MD, FACC, FSCAI
• Residual Cardiovascular Risk in Statin-Treated Patients with Elevated Triglycerides: Now We Can REDUCE-IT! ...Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

New Hopes for Heart Failure Management
Chairs: Mary Norine Walsh, MD, FACC, Stuart Katz, MD, James Fang, MD
Co-Chairs: Nihar Desai, MD, Rajesh Sachdeva, MD

• HFrEF vs HFpEF: What’s in a Name? .........................James Fang, MD
• Managing Heart Failure with Preserved Ejection Fraction...............Mary Norine Walsh, MD, FACC
• Management of Heart Failure with Reduced Ejection Fraction: Insights from SHIFT, PARADIGM HF and Others ....................Stuart Katz, MD
• Practical Strategies for Reducing HF Readmissions.............................James Fang, MD
• What Is in the Future Pipeline of HF Therapy? .........................Mary Norine Walsh, MD, FACC
Interventional Options in the Refractory Heart Failure: Identifying Right Patient and Choosing the Right Device........Darshak Karia, MD

Optimizing Clinical Outcomes by Optimizing the Management of Hyperlipidemia
(Sponsored by Ciné-Med, Inc) (Supported by Independent Educational Grant from Amgen) (CME)
Chairs: Alan Brown, MD, Jennifer Robinson, MD

- Welcome and Opening Remarks..................Alan Brown, MD
- LDL-C, Cardiovascular Outcomes, and Residual Risk: The Past and The Present ..........Sergio Fazio, MD, PhD
- The Discovery of PCKS9 and the Development of PCSK9 Inhibitors...............Carl Orringer, MD
- The Impact of Evolocumab on Coronary Atherosclerosis, Clinical Outcomes, and Neurocognitive Function: The GLAGOV, FOURIER, and EBBINGHAUS Trials..............................Jennifer Robinson, MD
- Panel Discussion
- Clinical Case Presentations to Highlight Recent ACC/AHA Guidelines and Populations of Special Interest for PCSK9 Inhibition......Sean Pokorney, MD, MBA
- Case 1: A 68-Year-Old Male with Inferior Wall STEMI 2 Years Ago and NSTEMI 1 Year Ago, LDL of 110mg/dL Despite Atorvastatin 80mg Daily..................Nihar Desai, MD, MPH
- Case 2: A 74-Year-Old Female with Peripheral Artery Disease and Non-Insulin Dependent Diabetes Who Has LDL-C of 100mg/dL on Maximally Tolerated Statin (Rosuvastatin 10mg Daily)..............................................Alan Brown, MD
- Panel Discussion with Audience Q&A
- Wrap-Up/Adjourn...............................Sergio Fazio, MD, PhD

Hyperlipidemia
(In Partnership with the National Lipid Association)
Chairs: Alan Brown, MD, Sergio Fazio, MD, PhD
Co-Chairs: Jennifer Robinson, MD, Carl Orringer, MD, Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

- The 2018 ACC/AHA/NLA Cholesterol Guideline: What has Changed?........................Carl Orringer, MD
- Cost Effectiveness of PCSK9 Inhibitors in the Era of Price Reduction..............Jennifer Robinson, MD
- Common Genetic Lipid Disorders that are Uncommonly Diagnosed: Part 1 Familial Hypercholesterolemia..............................Alan Brown, MD
- Common Genetic Lipid Disorders that are Uncommonly Diagnosed: Part 2 Lp(a) ......Sergio Fazio, MD, PhD
- The REDUCE IT Trial of EPA:Implications for Practice ....Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
- Summary and Insights of the Session..................................All faculty
Antithrombotics in Treatment of CAD and PAD
Chair: C. Michael Gibson, MD, FSCAI
Co-Chairs: Marc Bonaca, MD, MPH, Marie Gerhard-Herman, MD,
Roberto Giraldez, MD, PhD

• What is the Role of NOACs in Patients with CAD Alone: Is ASA + Low Dose Rivaroxaban Really Better than DAPT? .... Roberto Giraldez, MD, PhD

• What is the Optimal Antithrombotic Therapy in Patients with Both CAD + PAD? .. Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

• What is the Optimal Antithrombotic Therapy in Patients with PAD Alone? ...... Marie Gerhard-Herman, MD

• How Do We Risk Stratify Patients with PAD: Which Patients Benefit from Intensification of Antithrombotic Therapy? ...................................... Marc Bonaca, MD, MPH

• What is the Optimal Antithrombotic Therapy to Prevent Stroke? .................................................................................. TBA

• What is the Future of Antithrombotic Therapy: Emerging Therapies and Trials? ........ C. Michael Gibson, MD, FSCAI

Medical Management in Cardiology and Primary Care
Chairs: Ramesh Daggubati, MD, FACC, FSCAI, Matthew Martinez, MD,
Christian Erbel, MD

• Pregnancy: Evaluation of Common Cardiac Issues.........................Kalgi Modi, MD, FSCAI, FACCD

• Athlete Evaluation in Cardiology: What is a Must? ......................................................... Mathew Martinez, MD

• How to Evaluate and Manage Frequent PVC’s and PAC’s .......................... Sean Pokorney, MD, MBA

• Evaluation of Patient with Leg Edema ....................................................... Steven Dean, DO, FSVM, RPVI

Monday, June 24, 2019

NOAC in DVT and PE
Chairs: Gregory Piazza, MD, MS, Anthony Venbrux, MD, Teresa Carmen, MD

• How Long Should We Anticoagulate Patients with VTE and with What Dose?................................. Joe Lau, MD

• When Do Patients Need Advanced Therapies Beyond Anticoagulation with NOACs? ........... Gregory Piazza, MD, MS

• Should We Be Using IVC Filters Anymore? ...... Anthony Venbrux, MD

• Should Be Using NOACs or LMWH in Cancer-Associated VTE? .................................................. Teresa Carman, MD
Evolving Role of Cardiovascular Outcomes on Diabetic Management: When and How You Start New Drugs
Chairs: Prakash Deedwania, FACC, FAHA, FESC, Darren McGuire, MD, MHSc, John Stafford, MD, PhD
Moderator: Nihar Desai, MD

- Recent Data on CV Outcomes and Novel Diabetes Medications .......... Prakash Deedwania, FACC, FAHA, FESC
- Review of Updated ADA/ACE/AHA/ACC Guidelines on the Management of Patients with Cardiovascular Disease and Diabetes.......................... Darren McGuire, MD, MHSc
- Practical Steps for Getting Started: How to Initiate Newer Diabetes Medications for Your Patients with Cardiovascular Disease............................. Nihar Desai, MD
- The Next Frontier: Future Directions for Novel Diabetes Medications, Focus on Heart Failure.................................................. Darren McGuire, MD, MHSc

Trending Cardiovascular Nutrition and Lifestyles Controversies
Moderators: V. Chockalingam, MD, Ramesh Daggubati, MD, FACC, FSCAI, Koushik Reddy, MD,
Co-Moderators: Sripal Banagalore, MD, MHA, Parag Doshi, MD, FSCAI

- Weight Reduction Strategies for Resolving Emotional and Addictive Overeating .................. Joel Fuhrman, MD
- Mind Your Heart .......................................................... V. Chockalingam, MD
- Heart to Heart: Conversations with a Cardiologist ................................ Koushik Reddy, MD

Other Issues in General Medicine
Moderators: T.S.Dharmarajan, MD, MACP, FRCPE, Meenakshi Patel, MD, Naushira Pandya, MD, FACP

- Vitamin D and Supplements................................. Naushira Pandya, MD, FACP
- Hyponatremia in Heart Failure .......................... Meenakshi Patel, MD
- Hypertension Management In Elderly ......................... T.S.Dharmarajan, MD

Update on Hypertension Treatment 2019
Chairs: Sripal Bangalore, MD, Carl J. Pepine, MD, Paul Whelton, MD, MSc
Co-Moderators: Tudor Vagaonescu, MD, FSCAI

- What’s the Latest in the ACC/AHA BP Guidelines? .................... Paul Whelton, MD, MSc
- Resistant Hypertension: 2019 Update .................. Carl J. Pepine, MD
- Renal Denervation for Resistant Hypertension: Is it Dead?................. Sripal Bangalore, MD, MHA
Clinical Issues in General Cardiology
Moderators: Blasé Carabello, MD, Steven Bailey, MD, David Holmes, MD

• How to Evaluate and Provide Recommendations for Low Gradient, Low Output, and Normal Output Aortic Stenosis ............................. Blasé Carabello, MD
• Evaluation and Treatment Strategies in Patient with Severe MR and/or TR ......................... Steven Bailey, MD
• Newer Treatment Modalities in Treatment of MR and TR ........................................... Holger Thiele, MD
• Current State of PFO and Stroke: What Are the Latest Recommendations? .... Konstantinos Marmagkiolis, MD, FSCAI
• The Latest Clinical Trials of TAVR vs SAVR: The Essentials .................. David Wood, MD, FRCPC
• Primer on Evaluating Patients with PAD ............ Aditya Sharma, MBBS
• LAA Occluder in Atrial Fibrillation: Which Patient Should be Selected Based on Evidence? .......... David Holmes, MD

C³ Keynote Address and 15th Anniversary Celebration in Coronary Track Theater

Tuesday, June 25, 2019

Coronary Artery Disease: Diagnosis and Risk Stratification
Chairs: George Vetrovec, MD, MACC, MSCAI, Spencer King, MD, MACC, FSCAI,

• How Do You Risk Stratify a Patient Who Presents with Chest Pain? ......................... John Cahill, MD, FACC
• What Is the Role of Calcium Scoring in 2018? .................................................. Dinesh Kalra, MD, FACC

Debate: Diagnosis of CAD
• Coronary CTA Is the New Default Strategy .................................................... Robert Safian, MD, FSCAI
• Coronary Angiography Remains the Gold Standard .......................... George Vetrovec, MD, MACC, MSCAI
• Rebuttal .......................... Robert Safian, MD, FSCAI
• Rebuttal .......................... George Vetrovec, MD, MACC, MSCAI

• What Constitutes Optimal Medical Therapy in Stable Angina? .................................. TBA
• In Which Patients PCI is Still the Preferred Mode in Patients with Stable Angina? ........ Spencer King, MD, MACC, FSCAI
• Preoperative Cardiac Risk Stratification Prior to Noncardiac Surgery: Essentials .................. Ramesh Daggubati, MD, FACC, FSCAI

Schedule
Atrial Fibrillation: What's New in 2019?

Chairs: Samuel Asirvatham, MD, Dinesh Kalra, MD, FACC, Mintu Turakhia, MD, MAS

- Rhythm vs Rate Control: When to Refer for Ablation - Fallout from CABANA ............ Samuel Asirvatham, MD
- Which Drug Cocktail and NOAC for my Patient? Overview of US and ESC Guidelines .......... Roberto Giraldez, MD, PhD
- Is AF a Metabolic Disease? Recent Data on Lifestyle and Weight Loss to Manage AF .......... Kousik Krishnan, MD
- AF in Heart Failure: A Different Approach .................................. Parikshit Sharma, MD, MPH
- AF in Special Circumstances: HCM, Sleep Apnea, Thyroid Disease, Obesity, and Post-Surgical ...... Sean Pokorney, MD
- Wearable Devices and Digital Health in Arrhythmia Management: Where are we going? .......... Mintu Turakhia, MD, MAS
- New Energy Sources for Arrhythmia Ablation .................................... Samuel Asirvatham, MD

Trends in Cardiology

Moderators: Roman Zeltser, MD, FACC, George Vetrovec, MD, MACC, MSCAI, Sandeep Nathan, MD, MSc

- Aspirin in Primary and Secondary Cardiovascular Disease Prevention: Give, Not Give, Dosage, and Coatings ........................................ Vivian Rocha, MD
- Confronting Cardio-Oncology: An Emerging Epidemic ........................................ Olivia Hung, MD
- Cardiovascular Risk of Recreational and Addictive Drugs Including Cocaine, Marijuana, and Opioids ............................................................ Roman Zeltser, MD, FACC
- Artificial Intelligence Cardiology: Early Use and a Look to the Future ........... Mintu Turakhia, MD, MAS
- Should the Physician Engage in Social Media? How to Start Off, Patient Expectations, and Potential Landmines ........................................ Purvi Prawani, MD
Registration

Registration is open for the 15th Annual Complex Cardiovascular Catheter Therapeutics: Advanced Endovascular and Coronary Intervention Global Summit (C³)!

**If you are paying by credit card:** Visit www.c3conference.net and select “Register”. **If you are paying by check:** Mail check and your name/phone/email to the below address. Checks should be payable to ACHL/C³.

Mail checks to: 230 W Monroe Street, Suite 2300, Chicago, IL 60606

*You will be sent a code that allows you to register each person in your group through the conference website.*

<table>
<thead>
<tr>
<th>Conference</th>
<th>Registration Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before May 1, 2019</td>
</tr>
<tr>
<td>Full Conference: Industry</td>
<td>$650</td>
</tr>
<tr>
<td>Full Conference: Nurse/Technologist/Allied Health/Fellow/Resident/Student</td>
<td>$195</td>
</tr>
<tr>
<td>Podiatrist: Wound Care Program</td>
<td>$425</td>
</tr>
<tr>
<td>Full Conference: Physician</td>
<td>$495</td>
</tr>
</tbody>
</table>

Hotel Information

**Hilton Bonnet Creek**
14100 Bonnet Creek Resort Lane
Orlando, FL 32821
(407) 597-3600
www.hiltonbonnetcreek.com

Visit www.c3conference.net/Location to book your hotel room through the C³ Discounted Room Block Portal
Experience More at C³ 2019

The Best Live Demonstration Course in 2019
Renowned experts from globally-reputed medical centers will perform live cases.

Partnership Sessions
Highlight the Latest Clinical Challenges, organized by global interventional societies & clubs from Europe, Japan, China, Vietnam, Egypt, Thailand, Malaysia, Taiwan, Bangladesh, Pakistan, and South America.

Master Mentorship
If you are a Fellow & submit challenging cases or abstracts, the Top 3 will be selected by the C³ Scientific Committee and will have an opportunity to sit one-on-one with a Legend to review your presentation and gain insights and skills on presenting.

Challenging Case & Abstract Competition Sessions
Competition sessions for accepted abstract and case with the expert’s focus review. The top scientific case and abstract winner will get a $500 prize certificate!

Global Women Cardiac & Vascular Interventional Forum
For the third year in a row, C³ celebrates the contributions that women make to cardiovascular medicine. We are hosting two special sessions focused on women. The TOP TEN selected and accepted cases and scientific abstracts submitted by women will be featured in these sessions.

Science & Late-Breaking Research
The most influential & cutting-edge cardiovascular research for 2018-2019 will be presented with opportunity to simultaneously publish this research in leading journals.
Registration is open for the 15th Anniversary of the Complex Cardiovascular Catheter Therapeutics: Advanced Endovascular and Coronary Intervention Global Summit (C³)

C³ celebrates its’ 15th year anniversary this June 23-26, 2019 in Orlando, Florida at the Hilton Bonnet Creek. We hope you, your fellow colleagues, and friends will join us to share and learn in this dynamic educational opportunity!

#C32019 #C3Cardiology

© 2019 Academy for Continued Healthcare Learning
C3190